Chromosomal rearrangements, mutations and/or the aberrant expressions of PRDM2, PRDM3/MECOM and PRDM16 were reported in lymphoid/myeloid malignancies in accordance with their roles in the hematopoietic stem cell differentiation and homeostasis control [1,28]. The gene discussed is MECOM; the disease is myeloid neoplasm.